HFE-related hemochromatosis: An update for the rheumatologist

Current Rheumatology Reports

Volumn 16, Issue 1, 2014, Pages

  Husar Memmer, Emma ^a   Stadlmayr, Andreas ^b   Datz, Christian ^b   Zwerina, Jochen ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Arthropathy; Chondrocalcinosis; Clinical presentation; Diagnosis; Hemochromatosis; HFE gene; Iron overload; Screening

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTHROPATHY; ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFECT; GENE MUTATION; HAND RADIOGRAPHY; HEMOCHROMATOSIS; HEMOCHROMATOSIS ARTHROPATHY; HFE GENE; HUMAN; IRON OVERLOAD; LABORATORY DIAGNOSIS; MARKER GENE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PENETRANCE; PHLEBOTOMY; RHEUMATOLOGY; RISK FACTOR; SCREENING TEST; TREATMENT PLANNING; CHONDROCALCINOSIS; GENETICS; MUTATION; OSTEOARTHRITIS; RADIOGRAPHY; REVIEW; SYNOVITIS;

CHONDROCALCINOSIS; HEMOCHROMATOSIS; HUMANS; MUTATION; OSTEOARTHRITIS; SYNOVITIS;

EID: 84887793538     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0393-4     Document Type: Article

References (70)

1. Janssen MC, Swinkels DW. Hereditary haemochromatosis. Best Pract Res Clin Gastroenterol. 2009;23:171-83.
2. Trousseau A. Glycosurie, diabète sucré. Clinique médicale de l'Hôtel-Dieu de Paris. 1865;2:663-98.
3. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class 1-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408.
4. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256-62.
5. Datz C, Lalloz MR, Vogel W, et al. Predominance of the HLA-H Cys282Tyr mutation in Austrian patients with genetic haemochromatosis. J Hepatol. 1997;27:773-9.
6. Nielsen P, Carpinteiro S, Fischer R, et al. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. Br J Haematol. 1998;103:842-5.
7. Pedersen P, Milman N. Genetic screening for HFE hemochromatosis in 6,020 Danish men: penetrance of C282Y, H63D, and S65C variants. Ann Hematol. 2009;88:775-84.
8. Sassi R, Hmida S, Kaabi H, et al. Prevalence of C282Y and H63D mutations in the haemochromatosis (HFE) gene in Tunisian population. Ann Genet. 2004;47:325-30.
9. Viprakasit V, Vathesathokit P, Chinchang W, et al. Prevalence of HFE mutations among the Thai population and correlation with iron loading in haemoglobin E disorder. Eur J Haematol. 2004;73:43-9.
10. Castiella A, Zapata E, de Juan MD, et al. Significance of H63D homozygosity in a Basque population with hemochromatosis. J Gastroenterol Hepatol. 2010;25:1295-8.
11. Walsh A, Dixon JL, Ramm GA, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol. 2006;4:1403-10.
12. Gleeson F, Ryan E, Barrett S, Crowe J. Clinical expression of haemochromatosis in Irish C282Y homozygotes identified through family screening. Eur J Gastroenterol Hepatol. 2004;16:859-63.
13. Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166:294-301.
14. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358(3):221-30.
15. Fletcher LM, Dixon JL, Purdie DM, et al. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002;122:281-9.
16. Diwakaran HH, Befeler AS, Britton RS, et al. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol. 2002;36:687-91.
17. Piperno A, Fargion S, D'Alba R, et al. Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. J Hepatol. 1992;16:364-8.
18. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010;139:393-408.
19. Valenti L, Fracanzani AL, Rametta R, et al. Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. J Hepatol. 2012;57:1319-25.
20. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77-82.
21. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003;33:21-2.
22. Camaschella C, Roetto A, Calì A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000;25:14-5.
23. Mayr R, Griffiths WJ, Hermann M, et al. Identification of mutations in SLC40A1 that affect ferroportin function and phenotype of human ferroportin iron overload. Gastroenterology. 2011;140:2056-63.
24. Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol. 2010;53:941-9.
25. D'Alessio F, Hentze MW, Muckenthaler MU. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. J Hepatol. 2012;57:1052-60.
26. Krause A, Neitz S, Mägert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147-50.
27. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110:1037-44.
28. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-3.
29. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 2001;98:8780-5.
30. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003;361:669-73.
31. Vujic Spasic M, Kiss J, Herrmann T, et al. Physiologic systemic iron metabolism in mice deficient for duodenal Hfe. Blood. 2007;109:4511-7.
32. Vujić Spasić M, Kiss J, Herrmann T, et al. Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metab. 2008;7:173-8.
33. Morán-Jiménez MJ, Méndez M, Santiago B, et al. Hepcidin treatment in Hfe-/- mice diminishes plasma iron without affecting erythropoiesis. Eur J Clin Invest. 2010;40:511-7.
34. • Bardou-Jacquet E, Philip J, Lorho R, et al. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis. Hepatology. 2013. doi: 10.1002/hep.26570. An important clinical study supporting the hypothesis that hepatic iron sensing is dependent on intact HFE protein production.
35. Dwyer JP, Sarwar S, Egan B, et al. Hepatic iron overload following liver transplantation of a C282y homozygous allograft: a case report and literature review. Liver Int. 2011;31:1589-92.
36. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341:718-24.
37. European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53:3-22.
38. Schumacher Jr HR. Hemochromatosis and Arthritis. Arthritis Rheum. 1964;7:41-50.
39. McDonnell SM, Preston BL, Jewell SA, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med. 1999;106:619-24.
40. Wimalawansa SM, Alsamkari R. Unusual presentation of hemochromatosis as isolated metacarpophalangeal joint osteoarthritis: a case report. Hand (N Y). 2011;6:329-32.
41. Vaiopoulos G, Papanikolaou G, Politou M, et al. Arthropathy in juvenile hemochromatosis. Arthritis Rheum. 2003;48:227-30.
42. Abbott DF, Gresham GA. Arthropathy in transfusional siderosis. Br Med J. 1972;1:418-9.
43. Carroll GJ, Breidahl WH, Bulsara MK, Olynyk JK. Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load. Arthritis Rheum. 2011;63:286-94.
44. •• Sahinbegovic E, Dallos T, Aigner E, et al. Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum. 2010;62:3792-8. A systematic cross-sectional study showing disease manifestations and burden of musculoskeletal disease in hereditary hemochromatosis.
45. Dallos T, Sahinbegovic E, Stamm T, et al. Idiopathic hand osteoarthritis vs haemochromatosis arthropathy - a clinical, functional and radiographic study. Rheumatology (Oxford). 2013;52:910-5.
46. Davies MB, Saxby T. Ankle arthropathy of hemochromatosis: a case series and review of the literature. Foot Ankle Int. 2006;27:902-6.
47. Bijsterbosch J, Visser W, Kroon HM, et al. Thumb base involvement in symptomatic hand osteoarthritis is associated with more pain and functional disability. Ann Rheum Dis. 2010;69:585-7.
48. Valenti L, Fracanzani AL, Rossi V, et al. The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. J Rheumatol. 2008;35:153-8.
49. • Sahinbegovic E, Dallos T, Aigner E, et al. Hereditary hemochromatosis as a risk factor for joint replacement surgery. Am J Med. 2010;123:659-62. The first systematic study to reveal an increased risk for joint replacement surgery in hereditary hemochromatosis patients.
50. Wang Y, Gurrin LC, Wluka AE, et al. HFE C282Y homozygosity is associated with an increased risk of total hip replacement for osteoarthritis. Semin Arthritis Rheum. 2012;41:872-8.
51. • Elmberg M, Hultcrantz R, Simard JF, et al. Increased risk of arthropathies and joint replacement surgery in patients with genetic hemochromatosis: a study of 3,531 patients and their 11,794 first-degree relatives. Arthritis Care Res (Hoboken). 2013;65:678-85. A large-scale population based study confirming the increased risk of joint replacement surgery in hereditary hemochromatosis.
52. Richette P, Ottaviani S, Vicaut E, Bardin T. Musculoskeletal complications of hereditary hemochromatosis: a case-control study. J Rheumatol. 2010;37:2145-50.
53. Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med. 1989;110:430-6.
54. Valenti L, Varenna M, Fracanzani AL, et al. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int. 2009;20:549-55.
55. Guggenbuhl P, Deugnier Y, Boisdet JF, et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int. 2005;16:1809-14.
56. Nell-Duxneuner V, Axmann R, Husar-Memmer E, et al.: VCAM-1 serum levels are associated with arthropathy in hereditary haemochromatosis. Ann Rheum Dis. 2013 Apr 18. [Epub ahead of print]
57. Allen KJ, Bertalli NA, Osborne NJ, et al. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. Hepatology. 2010;52:925-33.
58. Aigner E, Schmid I, Osterreicher CH, et al. Contribution of anti-cyclic citrullinated peptide antibody and rheumatoid factor to the diagnosis of arthropathy in haemochromatosis. Ann Rheum Dis. 2007;66:1249-51.
59. Jäger HJ, Mehring U, Götz GF, et al. Radiological features of the visceral and skeletal involvement of hemochromatosis. Eur Radiol. 1997;7:1199-206.
60. Dallos T, Sahinbegovic E, Aigner E, et al. Validation of a radiographic scoring system for haemochromatosis arthropathy. Ann Rheum Dis. 2010;69:2145-51.
61. Montgomery KD, Williams JR, Sculco TP, DiCarlo E. Clinical and pathologic findings in hemochromatosis hip arthropathy. Clin Orthop Relat Res. 1998;347:179-87.
62. Frenzen K, Schäfer C, Keyßer G. Erosive and inflammatory joint changes in hereditary hemochromatosis arthropathy detected by low-field magnetic resonance imaging. Rheumatol Int. 2013;33:2061-7.
63. Heiland GR, Aigner E, Dallos T, et al. Synovial immunopathology in haemochromatosis arthropathy. Ann Rheum Dis. 2010;69:1214-9.
64. Carroll GJ, Sharma G, Upadhyay A, Jazayeri JA. Ferritin concentrations in synovial fluid are higher in osteoarthritis patients with HFE gene mutations (C282Y or H63D). Scand J Rheumatol. 2010;39:413-20.
65. Niederau C, Fischer R, Pürschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107-19.
66. Richette P, Eymard C, Deberg M, et al. Increase in type II collagen turnover after iron depletion in patients with hereditary haemochromatosis. Rheumatology (Oxford). 2010;49:760-6.
67. Announ N, Guerne PA. Treating difficult crystal pyrophosphate dihydrate deposition disease. Curr Rheumatol Rep. 2008;10:228-34.
68. Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-41.
69. McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 2008;58:631-3.
70. • Latourte A, Frazier A, Brière C, et al. Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands. Ann Rheum Dis. 2013;72:783-4. First description of a potential new treatment option for treatment of severe hemochromatosis arthropathy.